What Happened?
Cambridge, MA-based Goldfinch Biopharma Appointed Thomas Martz as Director of Corporate Development
Date of management change: December 15, 2016
Cambridge, MA-based Goldfinch Biopharma Appointed Thomas Martz as Director of Corporate Development
Goldfinch Bio is a biotechnology company that is singularly focused on discovering and developing precision therapies for kidney disease. Just as the goldfinch was a prominent figure of the Renaissance, Goldfinch Bio is leading a new age of therapeutic discovery to transform the treatment paradigm for patients with kidney disease. Goldfinch is integrating breakthroughs in kidney genetics and biology to identify new therapeutic targets and advance first-in-class drug candidates to treat patients with kidney disease. Our Product Engine will industrialize the integration of genetics and kidney biology and confer a differentiated ability to identify, validate, and pursue novel therapeutic targets to treat progressive kidney disease. At Goldfinch, we`re pioneering a new approach to discover and develop therapeutics that target the molecular basis of kidney disease. We`re looking for teammates who relish the challenge, and are compelled to leave a positive mark on the lives of colleagues and patients alike.
Thomas Martz is Director of Corporate Development at Goldfinch Biopharma. Previously, Thomas held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Bailey Karsin, Kalur Sai, Rothman Greg, Digby Gordon, Couch Elliott, Ayers Todd, Hussey Ron, Garbis Jason, Cockerham Tony, Shott Christopher, Pardo Cecilia
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.